Camino Ortega Emma, Gil de Gómez Ana Baroja, González Gamarra Amelia, Cuevas-Budhart Miguel Angel, García Klepzig José Luis, Gómez Del Pulgar García-Madrid Mercedes
Complutense University of Madrid, Spain; C.S. Goya, SERMAS, Madrid, Spain.
C.S. Goya, SERMAS, Madrid, Spain; Silvano Primary Care Center (Centro de Salud Silvano), Madrid, Spain.
Comput Biol Med. 2025 Jul;193:110411. doi: 10.1016/j.compbiomed.2025.110411. Epub 2025 May 27.
To evaluate the most effective development methods for mobile applications that support self-management of non-communicable diseases and to determine the features that enhance their effectiveness and user adoption.
The design was a systematic review of research papers published in the period 2019-2024. The review included randomized and quasi-experimental clinical trials. The search was performed in six databases (PubMed, Scopus, Scielo, CINAHL, Web of Science, and Clinical Trials). Bias and methodological quality were assessed using the RoB2 and MINORS tools.
The review included six studies involving 2421 patients across four countries. The applications demonstrated improvements in treatment adherence, self-efficacy, and control of clinical variables such as glycemia and blood pressure. The most effective applications incorporated therapeutic education, monitoring, and reminders. However, limitations were noted, including insufficient user involvement in early development stages, which could affect relevance and usability. The heterogeneity of study designs and populations, coupled with the lack of large-scale clinical trials, limits the generalizability of the findings. Additionally, variability in technological platforms and the absence of standardized evaluation metrics complicate outcome comparisons.
Mobile applications for chronic disease self-management are most effective when developed with a user-centered approach and continuous validation. Despite these findings, further research is necessary to generalize the results and optimize the integration of these applications into healthcare systems.
CRD42024571644.
评估支持非传染性疾病自我管理的移动应用程序最有效的开发方法，并确定增强其有效性和用户采用率的功能。
本设计是对2019年至2024年期间发表的研究论文进行系统综述。该综述包括随机和准实验性临床试验。检索在六个数据库（PubMed、Scopus、Scielo、CINAHL、科学网和临床试验）中进行。使用RoB2和MINORS工具评估偏倚和方法学质量。
该综述纳入了六项研究，涉及四个国家的2421名患者。这些应用程序在治疗依从性、自我效能以及血糖和血压等临床变量的控制方面均有改善。最有效的应用程序包含治疗教育、监测和提醒功能。然而，也发现了一些局限性，包括用户在早期开发阶段的参与不足，这可能会影响相关性和可用性。研究设计和人群的异质性，加上缺乏大规模临床试验，限制了研究结果的普遍性。此外，技术平台的多样性以及缺乏标准化的评估指标，使得结果比较变得复杂。
以用户为中心并持续进行验证来开发慢性病自我管理的移动应用程序最为有效。尽管有这些发现，但仍需要进一步研究以推广结果，并优化这些应用程序与医疗保健系统的整合。
PROSPERO注册号：CRD42024571644。
